Akihiko Yoshizawa

Papers

Total Citations

H-Index

About

Akihiko Yoshizawa is a thoracic surgeon and researcher whose work focuses on the intersection of immunotherapy and surgical oncology for lung cancer. His primary research areas include salvage surgery following immune checkpoint inhibitor (ICI) therapy for non-small cell lung cancer (NSCLC) and the management of rare mediastinal tumors. Yoshizawa’s major contribution is his pioneering investigation into the outcomes and characteristics of salvage surgery after ICI treatment for initially unresectable NSCLC—a critical, emerging field as ICIs transform advanced lung cancer care. His most-cited paper (2024, 6 citations) provides foundational data on surgical safety and survival in this novel context, helping to define when and how to operate after immunotherapy. He has also contributed to the literature on paratracheal middle mediastinal thymic carcinomas (2019), shedding light on a rare tumor subtype. While his citation counts are modest, his work addresses a timely, high-impact clinical question that is gaining attention as ICI use expands. For students and researchers, Yoshizawa’s research exemplifies how surgical oncology is adapting to the immunotherapy era, offering practical insights for multidisciplinary lung cancer management.